Tier 2 — strong

Sirtuins in Alzheimer's disease: mechanistic insights and therapeutic opportunities

Ning Bai, Shuhui Liu, Jiayi Wei, Biyu Zheng, Weiye Wang, Xiaoman Li, Jiaming Yang, Xiaoyu Song, Liang Wang, Fei Yi, Liu Cao
Trends in Pharmacological Sciences 2026 47(1):100-119

Bibliography

PubMed
PMID 41309432
DOI
10.1016/j.tips.2025.10.016

Study snapshot

DesignNarrative mechanistic and therapeutic review.
ModelPublished cellular, animal and human Alzheimer disease literature.
SampleNot applicable.
InterventionNot applicable.
DurationNot applicable.
EndpointsAmyloid biology; Tau pathology; Neuroinflammation; Sirtuin isoform mechanisms; Small-molecule modulators

What the study showed, in plain terms

This 2026 review places SIRT6 inside the broader sirtuin-Alzheimer landscape, where DNA repair, Tau biology, mitochondrial function and neuroinflammation are active targets but clinical evidence for SIRT6-specific treatment remains limited.

Key findings

The review evaluates distinct sirtuin isoforms in Alzheimer pathogenesis and therapeutic evidence for small-molecule modulators, emphasizing translational promise without established disease-modifying SIRT6 therapy.

What this study can and cannot tell us

It is a broad sirtuin review rather than a SIRT6-specific clinical systematic review, and most direct SIRT6 therapeutic evidence remains preclinical.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability